Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Capricor Therapeutics Inc Market Cap
The Capricor Therapeutics Inc (CAPR) share price is expected to increase by 173.78% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered CAPR. Price targets range from $25 at the low end to $77 at the high end. The current analyst consensus for CAPR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CAPR is a stock in Healthcare which has been forecasted to be worth $41.28571 as an average. On the higher end, the forecast price is $77 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end CAPR is forecasted to be $25 by Aydin Huseynov from Ladenburg Thalmann.
These are the latest 20 analyst ratings of CAPR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Catherine Novack Jones Trading | Buy | $40 | Initiates | Nov 18, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $30 | Maintains | Nov 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $77 | Reiterates | Nov 14, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $35 | Initiates | Oct 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $77 | Maintains | Oct 11, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | Oct 9, 2024 |
| Jason McCarthy Maxim Group | Buy | $25 | Maintains | Sep 25, 2024 |
| Leland Gershell Oppenheimer | Outperform | $43 | Maintains | Sep 25, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | Sep 24, 2024 |
| Leland Gershell Oppenheimer | Outperform | $15 | Reiterates | Sep 23, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $8 | Reiterates | Sep 20, 2024 |
| Jason McCarthy Maxim Group | Buy | $12 | Reiterates | Sep 17, 2024 |
| Leland Gershell Oppenheimer | Outperform | $15 | Maintains | Sep 17, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | Sep 17, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | Jul 2, 2024 |
| Leland Gershell Oppenheimer | Outperform | $14 | Initiates | May 17, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $8 | Reiterates | May 14, 2024 |
| Aydin Huseynov Ladenburg Thalmann | Buy | $25 | Maintains | May 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | May 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $40 | Reiterates | Apr 25, 2024 |
When did it IPO
2007
Staff Count
101
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Linda Marbán Ph.D.
Market Cap
$685.7M
In 2023, CAPR generated $25.2M in revenue, which was a increase of 886.81% from the previous year. This can be seen as a signal that CAPR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sat, 07 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Capricor Therapeutics is advancing deramiocel for DMD-related cardiomyopathy, with a BLA submission and possible FDA approval by 2025. Phase 2 trials show significant efficacy, but prior deals limit upside.
Why It Matters - Capricor's advancing therapy for DMD-related cardiomyopathy could lead to FDA approval and significant revenue streams, enhancing stock value despite limited upside from past deals.
Fri, 06 Dec 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Capricor Therapeutics has begun its rolling BLA submission for Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy, expected to complete by late 2024. They raised $86.3 million to fund operations into 2027.
Why It Matters - Capricor's BLA submission and positive study results enhance its growth prospects, while the recent funding secures operational stability, making it an attractive investment opportunity.
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Capricor Therapeutics (NASDAQ: CAPR) will present at upcoming investor conferences, focusing on its cell and exosome-based therapeutics for rare diseases.
Why It Matters - Capricor Therapeutics' participation in investor conferences can boost visibility, attract potential investors, and influence stock performance, signaling confidence in their biotech innovations.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Capricor Therapeutics, Inc. (NASDAQ:CAPR) will hold its Q3 2024 earnings conference call on November 13, 2024, at 4:30 PM ET, featuring executives and analysts from various firms.
Why It Matters - Capricor's Q3 earnings call will provide insights on financial performance and strategic direction, influencing investor sentiment and stock valuation.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Capricor Therapeutics (NASDAQ: CAPR) reported its Q3 financial results for 2024 and shared a corporate update on its cell and exosome-based therapeutics for rare diseases.
Why It Matters - Capricor's financial results and corporate updates can impact stock performance, indicating the company's growth potential and operational health, crucial for making investment decisions.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Capricor Therapeutics (CAPR) reported a quarterly loss of $0.38 per share, exceeding the Zacks estimate of $0.34 and worsening from a loss of $0.25 per share a year prior.
Why It Matters - Capricor's larger-than-expected quarterly loss could indicate worsening financial health, impacting investor confidence and potentially leading to stock price declines.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
